Literature DB >> 25700612

Investigating the microstructural and neurochemical environment within the basal ganglia of current methamphetamine abusers.

Joanne C Lin1, Reem K Jan1, Rob R Kydd2, Bruce R Russell3.   

Abstract

BACKGROUND: Methamphetamine is a highly addictive psychostimulant and the medical, social, and economic consequences associated with its use have become a major international problem. Current evidence has shown methamphetamine to be particularly neurotoxic to dopamine neurons and striatal structures within the basal ganglia. A previous study from our laboratory demonstrated larger putamen volumes in actively using methamphetamine-dependent participants. The purpose of this current study was to determine whether striatal structures in the same sample of participants also exhibit pathology on the microstructural and molecular level.
METHODS: Diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (MRS) were carried out in current methamphetamine users (n = 18) and healthy controls (n = 22) to investigate diffusion indices and neurometabolite levels in the basal ganglia.
RESULTS: Contrary to findings from previous DTI and MRS studies, no significant differences in diffusion indices or metabolite levels were observed in the basal ganglia regions of current methamphetamine users.
CONCLUSIONS: These findings differ from those reported in abstinent users and the absence of diffusion and neurochemical abnormalities may suggest that striatal enlargement in current methamphetamine use may be due to mechanisms other than edema and glial proliferation.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Basal ganglia; Diffusion tensor imaging (DTI); Magnetic resonance spectroscopy (MRS); Methamphetamine

Mesh:

Substances:

Year:  2015        PMID: 25700612     DOI: 10.1016/j.drugalcdep.2015.01.026

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  7 in total

Review 1.  The Utility of Magnetic Resonance Spectroscopy for Understanding Substance Use Disorders: A Systematic Review of the Literature.

Authors:  Tracy Hellem; Xianfeng Shi; Gwen Latendresse; Perry F Renshaw
Journal:  J Am Psychiatr Nurses Assoc       Date:  2015 Jul-Aug       Impact factor: 2.385

2.  Brain Microstructure and Impulsivity Differ between Current and Past Methamphetamine Users.

Authors:  Tamara Andres; Thomas Ernst; Kenichi Oishi; David Greenstein; Helenna Nakama; Linda Chang
Journal:  J Neuroimmune Pharmacol       Date:  2016-04-30       Impact factor: 4.147

Review 3.  Magnetic resonance spectroscopy studies of substance use disorders: Current landscape and potential future directions.

Authors:  Stephen J Kohut; Marc J Kaufman
Journal:  Pharmacol Biochem Behav       Date:  2020-12-14       Impact factor: 3.533

4.  White matter deficits assessed by diffusion tensor imaging and cognitive dysfunction in psychostimulant users with comorbid human immunodeficiency virus infection.

Authors:  Victor M Tang; Donna J Lang; Chantelle J Giesbrecht; William J Panenka; Taylor Willi; Ric M Procyshyn; Fidel Vila-Rodriguez; Willough Jenkins; Tania Lecomte; Heidi N Boyda; Ana Aleksic; G William MacEwan; William G Honer; Alasdair M Barr
Journal:  BMC Res Notes       Date:  2015-09-30

Review 5.  Meta-analysis of brain metabolite differences in HIV infection.

Authors:  Lydia Chelala; Erin E O'Connor; Peter B Barker; Thomas A Zeffiro
Journal:  Neuroimage Clin       Date:  2020-09-15       Impact factor: 4.881

6.  Time-Dependent Serum Brain-Derived Neurotrophic Factor Decline During Methamphetamine Withdrawal.

Authors:  Wenwei Ren; Jingyan Tao; Youdan Wei; Hang Su; Jie Zhang; Ying Xie; Jun Guo; Xiangyang Zhang; Hailing Zhang; Jincai He
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

Review 7.  Mean Diffusivity in the Dopaminergic System and Neural Differences Related to Dopaminergic System.

Authors:  Hikaru Takeuchi; Ryuta Kawashima
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.